Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

BACKGROUND: Recent cardiovascular outcome trials have shown that sodium–glucose co-transporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease (CKD) in patients with type 2 diabetes at high cardiovascular risk. Whether these benefits extend to CKD patients without type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Heerspink, Hiddo J L, Stefansson, Bergur V, Chertow, Glenn M, Correa-Rotter, Ricardo, Greene, Tom, Hou, Fan-Fan, Lindberg, Magnus, McMurray, John, Rossing, Peter, Toto, Roberto, Langkilde, Anna Maria, Wheeler, David C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005525/
https://www.ncbi.nlm.nih.gov/pubmed/32030417
http://dx.doi.org/10.1093/ndt/gfz290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005525/
https://www.ncbi.nlm.nih.gov/pubmed/32030417
http://dx.doi.org/10.1093/ndt/gfz290

Ejemplares similares